SGMT
Sagimet Biosciences Inc. NASDAQ Listed Jul 17, 2023$6.68
+2.30%
vs $6.53
Mkt Cap $216.1M
52w Low $4.55
37.4% of range
52w High $10.24
50d MA $6.89
200d MA $6.54
P/E (TTM)
—
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.0x
ROE
-45.8%
P/FCF
-4.7x
RSI (14)
34.80
ATR (14)
$0.33
Beta
3.21
50d MA
$6.89
200d MA
$6.54
Avg Volume
875.2K
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
155 Bovet Road · San Mateo, CA 94402 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | BMO | — | — | — | 7.71 | -0.1% | -0.3% | -0.5% | -0.7% | -3.0% | -6.4% | — |
| May 8, 2026 | BMO | — | — | — | 7.64 | +0.1% | +0.9% | -0.3% | -0.5% | -0.7% | -3.0% | — |
| May 7, 2026 | BMO | — | — | — | 8.38 | -0.6% | -8.8% | +0.9% | -0.3% | -0.5% | -0.7% | — |
| Mar 11, 2026 | TNS | -0.43 | -0.29 | +32.6% | 5.74 | -2.1% | -7.0% | -2.4% | -1.3% | +1.0% | -6.4% | — |
| Nov 13, 2025 | TNS | -0.41 | -0.40 | +2.4% | 7.74 | -1.0% | +0.1% | +0.8% | +0.1% | +0.4% | -7.4% | — |
| Aug 13, 2025 | TNS | -0.52 | -0.32 | +38.5% | 9.58 | -1.8% | -9.5% | -11.5% | -1.6% | -8.5% | +3.9% | — |
| May 8, 2025 | TNS | -0.79 | -0.56 | +29.1% | 3.20 | +0.9% | +1.9% | +1.5% | -3.9% | -2.5% | +6.8% | — |
| Mar 12, 2025 | TNS | -0.65 | -0.50 | +23.1% | 3.51 | -0.3% | +0.0% | +6.6% | +1.1% | +1.9% | +0.0% | — |
| Nov 14, 2024 | TNS | -0.47 | -0.45 | +4.3% | 5.18 | -2.5% | -8.7% | -7.8% | +1.1% | +2.5% | -0.4% | — |
| Aug 14, 2024 | TNS | -0.34 | -0.25 | +26.5% | 2.47 | +5.3% | +11.7% | -0.4% | +2.5% | +7.4% | +1.7% | — |
| May 15, 2024 | TNS | -0.41 | -0.23 | +43.9% | 4.62 | +1.3% | +2.8% | -2.7% | +2.6% | +1.1% | +6.1% | — |
| Mar 25, 2024 | TNS | -0.58 | -0.78 | -34.5% | 5.22 | +0.6% | +0.2% | +9.6% | -5.4% | -3.5% | +0.2% | — |
| Nov 13, 2023 | TNS | -1.02 | -0.35 | +65.7% | 2.23 | +5.8% | +13.0% | -2.0% | -5.7% | +27.0% | +1.7% | — |
| Jul 14, 2023 | TNS | -0.50 | -35.80 | -7060.0% | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | TNS | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Guggenheim | Maintains | Buy → Buy | — | $8.75 | $8.75 | +0.0% | -1.7% | -6.6% | -5.2% | +3.8% | -2.3% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.53 | $5.77 | +4.3% | +3.8% | -7.0% | -2.4% | -1.3% | +1.0% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.23 | $6.80 | +9.1% | +5.3% | -7.3% | -10.5% | +2.0% | -1.8% |
| Nov 14 | Citizens | Maintains | Market Outperform → Market Outperform | — | $7.74 | $7.66 | -1.0% | +0.1% | +0.8% | +0.1% | +0.4% | -7.4% |
| Oct 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.98 | $6.99 | +0.1% | +2.6% | +1.8% | +0.3% | +0.4% | -0.4% |
| Jun 6 | Jones Trading | Maintains | Buy → Buy | — | $4.78 | $4.78 | +0.0% | +16.3% | -4.1% | +11.4% | +4.2% | +39.1% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.51 | $3.50 | -0.3% | +0.0% | +6.6% | +1.1% | +1.9% | +0.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $3.59 | +1.4% | -4.0% | +3.2% | +0.0% | +6.6% | +1.1% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.18 | $5.05 | -2.5% | -8.7% | -7.8% | +1.1% | +2.5% | -0.4% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.34 | $5.29 | -0.9% | -3.6% | +3.5% | +1.7% | +7.2% | +3.3% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $3.16 | +1.3% | +9.0% | +21.2% | -0.7% | +1.7% | -4.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.47 | $2.60 | +5.3% | +11.7% | -0.4% | +2.5% | +7.4% | +1.7% |
| Aug 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.47 | $2.60 | +5.3% | +11.7% | -0.4% | +2.5% | +7.4% | +1.7% |
| Jul 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $3.42 | $3.40 | -0.6% | -7.6% | -7.3% | -2.7% | +3.9% | +5.1% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.79 | $4.59 | -4.2% | -13.6% | +1.9% | -6.4% | -1.5% | +1.0% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.57 | -1.7% | +1.1% | +3.8% | +1.6% | +7.7% | -10.3% |
| Jun 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.65 | $4.57 | -1.7% | +1.1% | +3.8% | +1.6% | +7.7% | -10.3% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.72 | +0.4% | +2.6% | +7.3% | +5.8% | -1.3% | -1.3% |
| May 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.70 | $4.72 | +0.4% | +2.6% | +7.3% | +5.8% | -1.3% | -1.3% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.62 | $4.68 | +1.3% | +2.8% | -2.7% | +2.6% | +1.1% | +6.1% |
| May 16 | Goldman Sachs | Maintains | Buy → Buy | — | $4.62 | $4.68 | +1.3% | +2.8% | -2.7% | +2.6% | +1.1% | +6.1% |
| Mar 26 | Goldman Sachs | Maintains | Buy → Buy | — | $5.22 | $5.25 | +0.6% | +0.2% | +9.6% | -5.4% | -3.5% | +0.2% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.35 | $6.56 | +3.3% | +3.6% | -8.8% | +4.0% | +28.4% | -7.4% |
| Jan 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.42 | $18.42 | +0.0% | -4.9% | -7.3% | -13.6% | -23.9% | -0.7% |
| Jan 23 | Goldman Sachs | Maintains | Buy → Buy | — | $18.42 | $18.42 | +0.0% | -4.9% | -7.3% | -13.6% | -23.9% | -0.7% |
| Jan 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.82 | $15.00 | +119.9% | +170.1% | -4.9% | -7.3% | -13.6% | -23.9% |
| Dec 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.06 | $4.10 | +1.0% | +2.2% | -4.1% | +1.5% | -10.1% | +5.5% |
No insider trades available.
8-K · 2.02
!! High
Sagimet Biosciences Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 1.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 1.01: Underwriting / Securities
Sagimet Biosciences secured $164.5 million in Series A funding through Leerink Partners, providing capital to advance its biopharmaceutical pipeline and operations.
Apr 28
8-K · 7.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 7.01: Regulation FD Disclosure
Sagimet Biosciences is updating its investor presentation materials for ongoing shareholder communications and roadshow meetings.
Apr 27
8-K · 7.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 7.01: Regulation FD Disclosure
Sagimet Biosciences disclosed updated investor presentation materials for ongoing meetings, suggesting management is actively communicating financial and operational updates to shareholders.
Apr 27
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A life sciences-focused executive with deep investment banking expertise joined one of these companies, potentially signaling strategic M&A activity or capital-raising plans ahead.
Mar 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Sagimet disclosed material information via press release and investor presentation on March 11, 2026, likely announcing clinical trial results or strategic developments that could significantly impact the biotech stock's valuation and investor sentiment.
Mar 11
8-K · 7.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 7.01: Regulation FD Disclosure
Sagimet Biosciences announced positive Phase 3 results for ASC40 in acne treatment, potentially advancing the drug toward regulatory approval and supporting future commercialization efforts.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,098,919 | $6M | New | Mar 2026 |
| 2 | Woodline Partners Lp | 1,000,943 | $5M | — | Mar 2026 |
| 3 | Marshall Wace, Llp | 966,253 | $5M | Added | Mar 2026 |
| 4 | Millennium Management | 862,303 | $5M | Added | Mar 2026 |
| 5 | Renaissance Technologies Llc | 625,469 | $3M | Added | Mar 2026 |
| 6 | D.e. Shaw & Co | 411,570 | $2M | Reduced | Mar 2026 |
| 7 | Hudson Bay Capital Management Lp | 304,472 | $2M | New | Dec 2025 |
| 8 | Blue Owl Capital Holdings Lp | 333,877 | $2M | Reduced | Mar 2026 |
| 9 | Raymond James Financial Inc | 317,550 | $2M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 293,934 | $2M | Added | Mar 2026 |
| 11 | Morgan Stanley | 178,488 | $1M | Reduced | Dec 2025 |
| 12 | Point72 Asset Management | 187,564 | $980K | Added | Mar 2026 |
| 13 | Qube Research & Technologies Ltd | 182,738 | $955K | Added | Mar 2026 |
| 14 | Fny Investment Advisers, Llc | 149,761 | $782K | Added | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 124,604 | $651K | Reduced | Mar 2026 |
| 16 | Jane Street Group, Llc | 92,436 | $547K | Added | Dec 2025 |
| 17 | Rb Capital Management, Llc | 97,000 | $507K | — | Mar 2026 |
| 18 | Dumac, Inc. | 71,192 | $372K | — | Mar 2026 |
| 19 | Citadel Advisors Llc | 68,173 | $356K | Added | Mar 2026 |
| 20 | Northern Trust Corp | 55,511 | $290K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$216.1M
Enterprise Value
$102.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.42x
P/B
1.94x
P/S
—
P/FCF
-4.73x
EV/EBITDA
—
Shares Out
32.3M
Financials (TTM)
Revenue
$0
Net Income
-$43.5M
EBITDA
-$46.1M
Free Cash Flow
-$45.6M
Op Cash Flow
-$45.6M
EPS Basic
$-1.58
EPS Diluted
$-1.35
EPS Forward
$-1.66
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$116.5M
Total Liab.
$5.1M
Total Equity
$111.4M
Cash
$113.1M
LT Debt
$0
Book Value/Sh
$3.44
Debt/Equity
0.00x
Current Ratio
22.82
Quick Ratio
22.82
Returns & Growth
ROE
-45.8%
ROA
-43.8%
ROIC
-51.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-9.0%
Price Returns
2W
-1.1%
1M
-9.2%
3M
+27.7%
6M
+1.0%
12M
+105.4%
Technicals
52W High
$10.24
52W Low
$4.55
50d MA
$6.89
200d MA
$6.54
RSI (14)
34.80
ATR (14)
$0.33
Beta
3.21
Avg Volume
875K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.00
High
$8.00
Low
$8.00
Median
$8.00
Data updated apr 27, 2026 1:00am
· Source: financialmodelingprep.com